Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Nov;48(11):1064–1066. doi: 10.1136/jcp.48.11.1064

Lack of correlation of P-glycoprotein expression with response to MIC chemotherapy in oesophageal cancer.

S J Darnton 1, K Jenner 1, R S Steyn 1, D R Ferry 1, H R Matthews 1
PMCID: PMC503018  PMID: 8543635

Abstract

The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC). Tumours were assessed following treatment and correlation with response sought. Of the squamous carcinomas, 74% (20/27) responded to MIC but only one expressed P-GP before and after treatment. Of the adenocarcinomas, 30% (three of 10) responded. Seven of the 10 adenocarcinomas expressed P-GP before treatment but all 10 were P-GP positive after chemotherapy. The difference in prevalence and induction of P-GP between the histological types was highly significant and may correlate with the greater response to MIC seen in squamous carcinomas compared with adenocarcinomas. P-GP cannot be used as a predictive marker of response as tumours express it inconsistently with response to MIC. Resistance to MIC may be due to other mechanisms.

Full text

PDF
1065

Images in this article

1065Image
on p.1065

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen S. M., Duffy J. P., Walker S. J., Darnton S. J., Cullen M. H., Matthews H. R. A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 1994;6(2):91–95. doi: 10.1016/s0936-6555(05)80110-4. [DOI] [PubMed] [Google Scholar]
  2. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  3. Ferry D. R., Kerr D. J. Multidrug resistance in cancer. BMJ. 1994 Jan 15;308(6922):148–149. doi: 10.1136/bmj.308.6922.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Robey-Cafferty S. S., Rutledge M. L., Bruner J. M. Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma. Am J Clin Pathol. 1990 Jan;93(1):1–7. doi: 10.1093/ajcp/93.1.1. [DOI] [PubMed] [Google Scholar]
  5. Saito T., Hikita M., Kohno K., Sato S., Takano H., Kobayashi M. Different sensitivities of human esophageal cancer cells to multiple anti-cancer agents and related mechanisms. Cancer. 1992 Nov 15;70(10):2402–2409. doi: 10.1002/1097-0142(19921115)70:10<2402::aid-cncr2820701005>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  6. Twentyman P. R., Fox N. E., Wright K. A., Bleehen N. M. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer. 1986 Apr;53(4):529–537. doi: 10.1038/bjc.1986.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Woodhouse J. R., Ferry D. R. The genetic basis of resistance to cancer chemotherapy. Ann Med. 1995 Apr;27(2):157–167. doi: 10.3109/07853899509031953. [DOI] [PubMed] [Google Scholar]
  8. Yuen A. R., Sikic B. I. Multidrug resistance in lymphomas. J Clin Oncol. 1994 Nov;12(11):2453–2459. doi: 10.1200/JCO.1994.12.11.2453. [DOI] [PubMed] [Google Scholar]
  9. Yusa K., Sato W., Yamazaki A., Tsukahara S., Tsuruo T. Cross-resistance of human multidrug-resistant cells to mitomycin C. Anticancer Res. 1991 May-Jun;11(3):1301–1304. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES